Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21094089 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Conditions: Chronic Lymphoid Leukemia;   Lymphoid Malignancies;   Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Peripheral T-cell Lymphoma
Intervention: Drug: ABT-263

Indicates status has not been verified in more than two years